S-23 is a selective androgen receptor modulator studied in rodents as a potential male contraceptive. Its reported muscle effects and hormonal suppression have not been tested for efficacy or long-term safety in people.
Key points
- The principal efficacy experiments were in rats, not athletes or patients.
- Androgenic effects and suppression of the reproductive axis were part of the investigated mechanism.
- A label describing S-23 does not establish purity or identity.
What the literature shows
Jones and colleagues characterized S-23 in rat models and explored its ability to suppress fertility when combined with an estrogen. Changes in reproductive hormones and tissue weights in this model cannot establish a safe or effective regimen for humans.
Earlier work on selective androgen receptor modulators for male contraception supplies background for the research strategy, but is not a human trial of S-23. Claims of predictable strength gains from S-23 remain untested in controlled human studies.
What remains unknown
- No controlled human efficacy or safety study establishes exposure, fertility recovery or cardiovascular risk.
- It is unknown whether retail products contain the stated compound or concentration.
Safety and monitoring implications
- Possible reproductive suppression makes self-experimentation especially concerning for anyone planning fertility.
- Seek clinical advice for persistent sexual, mood or fertility changes; do not interpret animal results as a human safety margin.
Cited literature
- 1.Jones A, Chen J, Hwang DJ, et al. (2008). Preclinical characterization of a selective androgen receptor modulator for hormonal male contraception. Endocrinology. Find on PubMed
- 2.Chen J, Hwang DJ, Bohl CE, et al. (2005). A selective androgen receptor modulator for hormonal male contraception. Journal of Pharmacology and Experimental Therapeutics. Find on PubMed
Community reports
Anecdotal — not scientific evidence
Lived experience is valuable context and often surfaces problems before the literature does. It is also uncontrolled, unverified and subject to bias, so it never overrides published findings here.
Editorial evidence status
MixedNo independently verified community reports were available for this analysis. Anecdotes have not been invented or treated as clinical evidence.
Buying S-23 in Australia: what to check first
APEDRA does not sell S-23 or any other product, and takes no commission from suppliers. If you are researching where to buy it, the biggest practical risk is not the compound itself but what is actually in the bottle: under-dosing, substitution with a different compound, and contamination are all documented in independent testing of online research chemicals.
- Ask for a batch-specific third-party lab report (HPLC/mass spectrometry), not a generic certificate.
- Check independent review platforms, not only reviews hosted on the seller's own site.
- Read the shipping, returns and refund policies before ordering.
- Be wary of prices far below the market or exaggerated results claims.
Compare Australian vendors independently · how we assess suppliers
Terms used here are defined in our glossary, and the evidence-grading scale explains what this analysis's grade means. If you believe something here is wrong, tell us.
This analysis is educational. It is not medical advice, a dosing recommendation, or an endorsement of use. Speak with a qualified medical practitioner about your circumstances.